iStock— GSK’s bepirovirsen both alone and in combination with nucleos(t)ide analogue therapy has shown functional cure in patients with chronic hepatitis B
— Addition of JNJ-3989 when administered sequentially with bepirovirsen may have the potential to further increase functional cure rates
— Transaction underscores GSK’s leadership in the treatment and prevention of infectious diseases and commitment to the development of oligonucleotide therapeutics
Read the full press release here.
Source : GSK
Related HIV and Co-Infections News
-
Hepatitis B: Updates from Aligos Therapeutics, Arbutus Biopharma Corporation and Precision BioSciences
-
EurekAlert!: Between 2.4 and 4.1 million people estimated to be living with chronic hepatitis B infection in Europe
-
The Rockefeller University: A new mouse model of virus-driven liver cancer may open the door to better diagnosis and treatments
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.